Pharma media agency serving US Rx, OTC, and medical device brands
Ichelon Consulting US is a specialist US pharma media agency. We plan and buy media for Rx brand teams, OTC portfolios and medical device manufacturers under an FDA-aware operating envelope — MLR-reviewed creative, DSCSA-aware messaging, HCP versus DTC audience walls, and adverse-event handling written into every activation. Multi-channel across Google, Meta, LinkedIn, programmatic, endemic HCP networks and connected TV.
- A pharma media agency plans and buys advertising for Rx, OTC and medical device brands under FDA promotional rules, DSCSA supply-chain messaging constraints and MLR (Medical, Legal, Regulatory) review workflows.
- Ichelon Consulting US runs pharma media across Google, Meta, LinkedIn, programmatic, endemic HCP networks and connected TV — with HCP audience walls and DTC fair-balance built into every campaign.
- Every creative is submitted for MLR review with change-tracked versions, ISI placement, and adverse-event reporting hooks connected to the brand's pharmacovigilance workflow.
- Delivery from Dallas HQ with pods that work ET, CT and PT hours. Retainers custom-scoped per engagement · from $499/month upward.
- Dallas, Texas LLC
- US client team · Central Time (CST)
- 25+ US healthcare clients
- BAA signed with every client
- HIPAA compliance training across client and delivery teams
- Contracts and invoices in USD
-
Primary Care · North Dallas, TXCase study →
-
MedSpa · North Dallas, TX
-
Skin Care · Beverly Hills, CA
-
Dental · Christiansburg, VACase study →
-
Pediatrics · Blacksburg, VACase study →
-
Pediatric Dentistry · Blacksburg, VACase study →
-
Dental · Roanoke, VACase study →
-
Functional Medicine · Telehealth · USACase study →
“They were able to get all my ideas and work with me over a period of three to four months and create this amazing website. It's super customized, very modern, and it incorporates all the elements that I had wanted — the patient portal, nice pictures, a very interactive website, patient reviews. I would highly recommend their company to anyone who wants to make an excellent website.”
What a pharma media agency actually does
A pharma media agency sits between a pharmaceutical, OTC or medical device brand and the paid channels — with a compliance layer between them that a general media agency does not carry. The brand hands the agency a promotional intent, an approved label indication and an ISI (Important Safety Information) block. The agency turns that into campaigns that live inside FDA promotional rules, DSCSA constraints on supply-chain claims, and per-audience walls that separate healthcare professional targeting from direct-to-consumer targeting.
The mechanics of paid buying — bid strategies, audience segmentation, creative rotation, frequency management — are broadly the same as any performance agency runs. What is not the same is the artefact library: every branded ad ships with fair-balance, every unbranded disease-awareness campaign is walled off from branded assets, every landing page carries the current ISI, and every ad platform's default optimization gets overridden where it would otherwise chase clicks into off-label territory.
Ichelon Consulting US operates as the pharma media agency for US Rx brand teams that need a specialist media pod, not a full agency-of-record contract. We plug into the brand's existing MLR workflow, the pharmacovigilance team's AE reporting pipeline, and the brand lead's KPI dashboard — and we deliver from Dallas with pods that work every US time zone.
FDA-aware media planning
Media planning inside pharma is a different exercise from consumer performance planning. Budget allocation, channel mix and creative rotation all have to respect promotional rules that shift with label updates, DSCSA supply-chain notices and FDA guidance revisions. Every plan Ichelon Consulting US writes for a pharma brand is scoped against six anchors before it goes into a media buy.
1. Label-anchored messaging
Every creative claim traces back to a specific line of the approved label. Off-label territory is flagged in briefs and either killed or rebuilt against unbranded disease-awareness placements with a firewall to any branded property.
2. Fair-balance and ISI
Every branded ad carries risk information in the ratio the brand's MLR team requires. Landing pages carry the current ISI above the fold. Video and audio placements have ISI voiceovers at the required cadence.
3. DSCSA-aware supply-chain messaging
Supply-chain claims — availability, distribution channel, pharmacy access — are scoped against the DSCSA-mandated data the brand has published. No availability claims that outrun the DSCSA-verified distribution footprint.
4. Media mix by audience type
HCP media mix and DTC media mix are planned as separate flights with separate creative libraries. Cross-audience remarketing is walled off — an HCP audience never receives DTC creative, a DTC audience never receives HCP creative.
5. Frequency and burn-out modeling
Frequency capped per identity, not per cookie or device. Creative burn-out modeled against MLR turnaround — no plan commits to a rotation cadence that MLR cannot service.
6. Adverse event capture
Every touchpoint that could return an AE report — comments, DMs, lead forms, chat — is instrumented to route the report to the brand's pharmacovigilance workflow within the FDA-mandated 24-hour window.
HCP versus DTC audience targeting
The single hardest part of pharma media is keeping the HCP audience and the DTC audience on separate rails. Every platform's default optimization wants to blur that line — a lookalike here, an interest overlap there, a broad-audience expansion prompt from the ad platform's own AI recommendation. Ichelon Consulting US's activation team overrides those defaults every time.
HCP targeting layer
NPI-based audience matches through the endemic HCP networks, LinkedIn job-title and industry targeting layered with specialty and years-of-practice signals, and programmatic contextual placements on peer-reviewed publisher inventory. Every HCP creative uses HCP-appropriate language, references the label's indication as it was approved for prescribers, and links to HCP-gated landing pages.
DTC targeting layer
Condition and symptom-intent targeting on Google, Meta and connected TV — with the label's DTC-appropriate language, fair-balance in every unit, and "talk to your doctor" as the primary call to action. Landing pages carry the current ISI, patient-friendly explanations, and a doctor-discussion guide download that carries proper consent for follow-up communication.
Cross-audience firewalls
Retargeting audiences are scoped so an HCP visitor to an HCP-gated page never ends up in a DTC lookalike, and a DTC visitor to a patient page never ends up in an HCP audience seed. This is boring, unglamorous audience-plumbing work — and it is where general media agencies most often trip a compliance review.
Compliance workflows — MLR review and pharmacovigilance
Every creative and every landing page ships through the brand's MLR review workflow before it goes live. Every touchpoint that can surface a patient adverse event is wired into the brand's pharmacovigilance intake within the FDA-mandated 24-hour window.
MLR review workflow
Creative submitted with change-tracked versions, source citations for every claim, ISI placement and fair-balance ratios that match the brand's MLR SOP. Turnaround planned into the media flight — no plan commits to a cadence MLR cannot service.
Adverse event routing
Comment, DM, form, chat and paid-social reply surfaces monitored for AE-shaped content. Reports routed to the brand's pharmacovigilance intake in under 24 hours, with the reporter-consent captured in the ad platform's own artefact.
HIPAA on tracking
No PHI in ad-platform events. Conversion payloads scrubbed of condition, prescription-status and provider identity. Server-side conversion API forwards hashed identifiers only.
Pharma media agency coverage
Ichelon Consulting US's Dallas HQ services US pharma clients nationally. Media is bought on national inventory; MLR coordination runs against the brand's headquarters wherever it sits — Boston, New York, New Jersey pharma corridor, San Francisco Bay biotech cluster, Chicago, Philadelphia and Washington DC included.
Trifecta-powered — organic and paid on one stack
Ichelon's Search Intelligence Trifecta — Angryturtle, SIE and YODA — sits under every pharma media engagement. Paid media buys the query today; SIE earns the organic ranking tomorrow so the same query is free next quarter. YODA builds the HCP and DTC video library that paid video spend can amplify. Angryturtle runs the brand's Google presence around the HCP-versus-DTC wall.
Angryturtle · GBP OS
Brand-owned Google Business Profiles for pharma corporate presence and HCP-facing patient-support program locations. Solo plan from $29/month.
SIE · Search Intelligence Engine
Topic map and entity graph across the brand's disease-awareness territory. Content briefs anchored to MLR-safe claims and AI-Overview-friendly structure.
YODA · YouTube AIO
HCP explainer library and DTC disease-awareness video library on separate channels with separate creative libraries — walled off in the exact same pattern paid media uses.
Backed by ICG global leadership
Every US pharma media engagement has direct line-of-sight to the Ichelon Consulting Group Leadership Team. Brand teams get a member of the Leadership Team in the room for scoping and quarterly review — the people who scope your engagement are the same people who read the monthly report.
Our own tools run inside every engagement
Ichelon Consulting US uses software built by our own product team. Practices can also use most tools on their own, billed in USD.
Pharma media agency — common questions
What is a pharma media agency and how is it different from a general media agency?
A pharma media agency plans and buys paid media for Rx, OTC and medical device brands under FDA promotional rules, DSCSA supply-chain constraints and MLR (Medical, Legal, Regulatory) review workflows. A general media agency runs the same media without those layers — which is why pharma brands routinely have to rescope campaigns after a general agency's work fails MLR review.
Do you handle MLR review coordination?
Yes. Creative is submitted with change-tracked versions, source citations for every claim, ISI placement and fair-balance ratios that match the brand's MLR SOP. We plan media flights around MLR turnaround so no plan commits to a rotation cadence that MLR cannot service.
How do you handle HCP versus DTC audience targeting?
HCP and DTC audiences are planned as separate flights with separate creative libraries. Retargeting is walled off — an HCP visitor never ends up in a DTC lookalike, a DTC visitor never ends up in an HCP seed. NPI-based matching handles HCP targeting; condition and symptom-intent targeting handles DTC.
How is adverse event reporting handled?
Every touchpoint that can surface a patient AE — comments, DMs, lead forms, chat and paid-social replies — is instrumented to route reports to the brand's pharmacovigilance intake within the FDA-mandated 24-hour window, with reporter-consent captured in the ad platform's own artefact.
Which channels do you buy?
Google Ads, Meta Ads, LinkedIn, programmatic display, endemic HCP publisher networks, connected TV, YouTube, and emerging AI answer engine inventory as it opens up. Media spend passes through at platform cost with a clear management-fee line.
What does a pharma media engagement cost?
Retainers are custom-scoped per engagement · from $499/month for tightly-scoped single-brand work, scaling with brand count, MLR volume and media spend. Product SKUs such as Angryturtle (from $29/month) run in parallel for GBP density.
Scope your US pharma media engagement
Book a 30-minute scoping call with a member of the Leadership Team, email the US practice lead, or WhatsApp us in your time zone.